|
|
- 2018
长链非编码RNA DOCK9-AS2对甲状腺乳头状癌细胞增殖和迁移的影响
|
Abstract:
摘要：目的 检测长链非编码RNA DOCK9-AS2在甲状腺乳头状癌(PTC)中的表达水平及对PTC细胞增殖、迁移能力的影响。方法 收集2016年6月至2017年6月间在南京医科大学第一附属医院手术切除的PTC标本及对应的癌旁组织，采用qRT-PCR检测62对组织中DOCK9-AS2的表达，并分析其与患者临床病理资料的关系。通过细胞转染技术构建沉默DOCK9-AS2的甲状腺癌BCPAP细胞株，用CCK8方法检测DOCK9-AS2对PTC细胞增殖能力的影响；划痕实验观察沉默下调DOCK9-AS2的表达对细胞侵袭转移能力的影响。结果 DOCK9-AS2在PTC的mRNA表达水平(0.0097±0.0044)高于癌旁组织(0.0026±0.0010)，差异具有统计学意义(P<0.05)。DOCK9-AS2在PTC组织中的表达与淋巴结转移、腺外侵犯有关(P<0.05)。在BCPAP细胞中下调DOCK9-AS2的表达时，PTC细胞的增殖和侵袭转移能力减弱(P<0.05)。结论 DOCK9-AS2在PTC中表达显著增高，沉默DOCK9-AS2的表达可抑制PTC细胞的增殖、侵袭和转移。
ABSTRACT: Objective? ?To detect the expression of long non-coding RNAs (lncRNAs) DOCK9-AS2 in papillary thyroid carcinoma (PTC) and its effects on the proliferation and migration of PTC cells. Methods?? PTC samples and the corresponding adjacent tissues were collected from The First Affiliated Hospital of Nanjing Medical University during June 2016 and June 2017. The qRT-PCR was performed to detected the expression of DOCK9-AS2 in the tissues, and the relationship between DOCK9-AS2 expression and the patients？？ clinicopathological data was analyzed. The cell transfection technology was used to establish the PTC BCPAP cell downregulating DOCK9-AS2 stably. CCK8 was carried out to investigate the effect of DOCK9-AS2 on the proliferation of the BCPAP cells. The wound-healing assay was used to dectect the effect of DOCK9-AS2 on the migration of the BCPAP cells. Results?? The expression of DOCK9-AS2 in PTC tissues (0.0097±0.0044) was significantly higher than that of adjacent tissues (0.0026±0.0010) (P<0.05). The expression of DOCK9-AS2 in PTC tissues was related to lymph node metastasis and extra-thyroid invasion (P<0.05). Down-regulation of DOCK9-AS2 could suppress the proliferation and invasion of the BCPAP cells (P<0.05). Conclusion?? The expression of DOCK9-AS2 in PTC was significantly increased, and downregulating DOCK9-AS2 could inhibit the proliferation and migration of PTC cells
| [1] | HAFEZ MT, REFKY B, EIWAHAB KA, et al. Axillary lymph nodes metastasis in a patient with recurrent papillary thyroid cancer: A case report[J]. J Med Case Rep, 2015, 9(1):890-894. |
| [2] | ZHAO JJ, HAO S, WANG LL, et al. Long non-coding RNA ANRIL promotes the invasion and metastasis of thyroid cancer cells through TGF-beta/Smad signaling pathway[J]. Oncotarget, 2016, 7(36):57903-57918. |
| [3] | KANG L, SUN J, WEN X, et al. Aberrant allele―switch imprinting of a novelIGFlR intragenic antisense non-coding RNA in breast cancers[J]. Eur J Cancer, 2014, 51(2):260-270. |
| [4] | BUNCH H. Gene regulation of mammalian long non-coding RNA[J]. Mol Genet Genomics, 2017, 89(4):110-119. |
| [5] | PAN YF, FENG L, ZHANG XQ, et al. Role of long non-coding RNAs in gene regulation andoncogenesis[J]. Chin Med J (Eng1), 2011, 124(15):2378-2383. |
| [6] | XU D, LV X, WANG S, et al. Risk factors for predicting central lymph node metastasis in papillary thyroidmicrocarcinoma[J]. Int J Clin Exp Pathol, 2014, 7(9):6199-6205. |
| [7] | 曹衡玉，何云，杨红，等. 彩超探查甲状腺癌主要供血动脉的血流动力学研究[J]. 中国超声医学杂志, 2010, 26(8):26-28. |
| [8] | WATTERS DA, AHUJA AT, EVANS RM, et al.RoIe of ultrasound in the management of thyroid nodules[J]. Am J Surg, 1992, 164:654-657. |
| [9] | LANNUCCILLI JD, CROANA JJ, MONCHIC JM. Risk for malignancy of thyroid nodules as assessed bysonographiccriteria: The need for biopsy[J]. Ultrasound Med, 2004, 23(11):1455-1464. |
| [10] | ROMAN BR, MORRIS LG, DAVIES L. The thyroid cancer epidemic, 2017 perspective[J]. Curr Opin Endocrinol Diabetes Obes, 2017, 24(5):332-336. |
| [11] | SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics[J]. CA Cancer J Clin, 2012, 62(1):10-29. |
| [12] | 丁金旺，周荣璨，罗中尧，等. 34βE12、Galectin-3及HBME-1在甲状腺良、恶性结节中的表达差异及临床诊断价值[J]. 中国耳鼻咽喉头颈外科, 2016, 23(2):88-92. |
| [13] | PARK CH, UH KJ, MULLIGAN BP, et al. Analysis of imprinted gene expression in normal fertilized anduniparental preimplantation porcine embryos[J]. PLoS One, 2011, 6(7):e22216. |
| [14] | 巩有方，赵现彬，张浩，等. 甲状腺乳头状癌组织中CD105、VEGF-C表达与其转移的关系[J]. 中国医师杂志, 2009, 11(9):1253-1255. |
| [15] | BILIMORIA KY, BENTREM DJ, KO CY, et al. Extent of surgery affects survival for papillary thyroid cancer[J]. Ann Surg, 2007, 246(3):375-381. |
| [16] | PUXEDDU E, MORETTI S. Clinical prognosis in BRAF-mutated PTC[J]. Arq Bras Endocrinol Metabol, 2007, 51(5):736-747. |
| [17] | RAO A, RAJKUMAR T, MANI S. Perspectives of longnoncoding RNAs in cancer[J]. Mol Biol Rep, 2017, 44(2):203-218. |
